Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEOGENOMICS INCNEO · Entity 2096 | Director | June 23, 2026 | June 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEOGENOMICS INC
Report date June 23, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.20 · Expires 2036-06-01 | Direct | 9,784 |
Reported balance
After 2026-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-23 · Grant · Acquired 9,784 · Balance 9,784 |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 14,125 |
Reported balance
After 2026-06-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-23 · Grant · Acquired 14,125 · Balance 14,125 F1: Once vested, the shares of common stock are not subject to expiration. |
Filing footnotes · ownership attribution and instrument terms
F1: Once vested, the shares of common stock are not subject to expiration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 23, 2026 Filed Jun 25, 2026 20:09 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantRestricted Stock Unit · Derivative | 14,125 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-045501 · wk-form4_1782418171.xml · derivative · entry 2 Starrett Carolyn S · CIK 0002141979 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,125 Underlying: Common Stock · 14,125 shares Expires not disclosed F1 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| June 23, 2026 Filed Jun 25, 2026 20:09 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 9,784 | $0.00 Strike: $11.20 | $0.00 |
DisclosureSEC source: 0001628280-26-045501 · wk-form4_1782418171.xml · derivative · entry 1 Starrett Carolyn S · CIK 0002141979 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,784 Underlying: Common Stock · 9,784 shares Expires 2036-06-01 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.